WACKER BIOSOLUTIONS

In 2019, WACKER BIOSOLUTIONS lifted its sales by 7.0 percent to €243.0 million (2018: €227.0 million). The main impetus came from higher volumes and positive exchange-rate effects. Lower prices, on the other hand, slowed sales growth. The division posted its biggest gains in biopharmaceuticals, where sales benefited from new production capacity in Amsterdam and high utilization rates at German sites. In regional terms, sales performance was good in the Americas and Asia.

At €31.1 million, was significantly higher year over year (2018: €23.5 million). This increase was fueled by volume growth, by higher plant utilization for biopharmaceuticals and by an improved cost structure. The EBITDA margin was 12.8 percent (2018: 10.4 percent).

Capital expenditures declined year over year to €13.2 million (2018: €17.9 million), a decrease of 26.3 percent. One investment focus was the new biologics production plant in Amsterdam.

As of December 31, 2019, the division had 754 employees (Dec. 31, 2018: 709).

 (XLS:) Download XLS
Key Data: WACKER BIOSOLUTIONS

 

 

 

 

 

€ million

 

2019

 

2018

 

2017

 

20161

 

2015

1

Reclassification of costs from selling expenses to R&D expenses starting in 2016

 

 

 

 

 

 

 

 

 

 

 

Total sales

 

243.0

 

227.0

 

205.9

 

206.4

 

197.1

EBITDA

 

31.1

 

23.5

 

37.5

 

37.0

 

32.2

EBITDA margin (%)

 

12.8

 

10.4

 

18.2

 

17.9

 

16.3

EBIT

 

14.0

 

9.8

 

26.1

 

25.7

 

21.0

Capital expenditures

 

13.2

 

17.9

 

15.7

 

9.1

 

6.2

R&D expenses

 

6.4

 

6.3

 

6.0

 

6.2

 

6.1

Employees (December 31, number)

 

754

 

709

 

533

 

510

 

491

EBITDA
Earnings before interest, taxes, depreciation and amortization.

todo Vorjahresvergleich